Orfenix

Orfenix is a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies for rare and orphan diseases. The company's primary focus is on Wilson's disease, a rare genetic disorder that causes copper to accumulate in the body. Its lead product, ORFX-001, is a novel, room-temperature stable formulation of trientine dihydrochloride designed to improve patient compliance and ease of use compared to traditional refrigerated versions. Founded in 2017 and based in the United Kingdom, Orfenix sought to address significant unmet needs in metabolic medicine. In September 2020, the company was acquired by AOP Orphan Pharmaceuticals (now AOP Health) to expand their international rare disease portfolio. This acquisition integrated Orfenix's specialized copper-chelating expertise into AOP's broader commercial infrastructure.